Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy.

Platinum-based neoadjuvant chemotherapy prior to radical cystectomy is the preferred treatment for muscle-invasive bladder cancer despite modest survival benefit and significant associated toxicities. Here, we profile the global proteome of muscle-invasive bladder cancers pre- and post-neoadjuvant chemotherapy treatment using archival formalin-fixed paraffin-embedded tissue. We identify four pre-neoadjuvant chemotherapy proteomic clusters with distinct biology and response to therapy and integrate these with transcriptomic subtypes and immunohistochemistry.

Discrimination of T-Stage Using Tumor Weight and Size: A Potential Approach to Guide Perioperative Decision-Making in Patients with Bladder Cancer.

Introduction: The aims of the study were to examine the value of tumor size, weight, and density in predicting pathological tumor stage in patients with suspected bladder cancer (BCa), minimize inter-observer variability of estimated tumor size, and thus provide a more objective instrument to describe the extent of local tumor growth.

Methods: An institutional dataset of 588 consecutive patients undergoing transurethral resection of bladder tumor (TUR-BT) for suspected BCa from 05/2016 to 09/2018 was used. Separate Mann-Whitney U tests examined differences in each unit between non-muscle-invasive BCa (NMIBC) and muscle-invasive BCa (MIBC) and between Ta/carcinoma in situ and T1 NMIBC.

Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study.

Purpose: The PURE-01 clinical trial reported the use of neoadjuvant treatment with pembrolizumab prior to radical cystectomy (RC) in patients with muscle-invasive bladder. Specific molecular subtypes and immune signatures were reported to be associated with a favorable survival. However, reports on the detailed tumor biology of patients relapsing after neoadjuvant pembrolizumab are lacking.